IRBM’s goal will be to help ensure a more resilient global response to future epidemics by producing second generation vaccines and treatments for SARS-CoV-2 and new coronaviruses.
List view / Grid view
European Investment Bank (EIB)
Collaborating with global partners BioNTech will work to develop a safe and effective malaria vaccine and set up its sustainable supply for the African continent.
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.
The European Investment Bank (EIB), in partnership with the European Commission (EC), have pledged an additional €4.9 billion for use in the global coronavirus response funds.
The Coalition for Epidemic Preparedness Innovations (CEPI) and European Investment Bank (EIB) will work together to identify and fund vaccine projects for infectious diseases.